VIMOVO

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Estonia, Finland, Ireland, Lithuania, Netherlands, Romania, South Africa, Spain, UK.

Active ingredients

The drug VIMOVO contains a combination of these active pharmaceutical ingredients (APIs):

1	Naproxen UNII 57Y76R9ATQ - NAPROXEN
	Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis.
	Read more about Naproxen
2	Esomeprazole UNII R6DXU4WAY9 - ESOMEPRAZOLE MAGNESIUM
	Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+ K+ -ATPase – the acid pump and inhibits both basal and stimulated acid secretion.
	Read more about Esomeprazole

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VIMOVO Delayed release tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M01AE52	Naproxen and esomeprazole	M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AE Propionic acid derivatives
Discover more medicines within M01AE52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	542820040006917, 542820040007017
CA	Health Products and Food Branch	02361701, 02361728
EE	Ravimiamet	1437768, 1437779, 1437780, 1437791, 1437803, 1437814, 1437825, 1460179
ES	Centro de información online de medicamentos de la AEMPS	73182
FI	Lääkealan turvallisuus- ja kehittämiskeskus	431530
GB	Medicines & Healthcare Products Regulatory Agency	182339
IE	Health Products Regulatory Authority	23216
LT	Valstybinė vaistų kontrolės tarnyba	1050688, 1050916, 1058591, 1058592, 1058593, 1058594, 1058595, 1058596, 1058597, 1058598, 1058599, 1058600, 1089161
NL	Z-Index G-Standaard, PRK	95710
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68965001, W68965002, W68965003, W68965004, W68965005, W68965006, W68965007, W68965008, W68965009, W68965010, W68965011, W68965012, W68965013, W68965014, W68965015, W68965016, W68965017, W68965018, W68965019, W68965020, W68965021, W68965022, W68965023, W68965024, W68965025, W68965026, W68965027, W68965028, W68965029, W68965030, W68965031, W68965032, W68965033, W68965034
US	FDA, National Drug Code	75987-030, 75987-031
ZA	Health Products Regulatory Authority	45/3.1/0179